Supportive Care in Cancer

, Volume 26, Issue 3, pp 1013–1016 | Cite as

A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation

  • Julia ZecchiniEmail author
  • Kendra Yum
  • Amir Steinberg
  • Cardinale Smith
  • Sara Kim
Original Article


Filgrastim-sndz (Zarxio®) was approved by the FDA in March 2015 as a biosimilar product of its reference product, filgrastim (Neupogen®) for all five indications. The NCCN Clinical Practice Guidelines has incorporated filgrastim-sndz into its recommendations as a category 1 recommendation for use in settings of febrile neutropenia, myelosuppressive chemotherapy administration, and post-hematopoietic stem cell transplant (HSCT). As a cost-saving initiative, our institution switched from filgrastim to filgrastim-sndz for all indications starting in March 2016. The purpose of this study was to assess for any difference in clinical or safety outcomes between filgrastim and filgrastim-sndz. This is an IRB-approved, single institution, 1-year retrospective chart review (September 2015 to August 2016) conducted in hospitalized adults who received either filgrastim or filgrastim-sndz either for prophylaxis of chemotherapy-induced myelosuppression or for neutrophil recovery after autologous HSCT. Our data showed no differences in duration of G-CSF therapy (7.96 vs. 8.5 days, P = 0.36), white blood count (WBC) (8.99 vs. 8.04, P = 0.28), absolute neutrophil count (ANC) (7.62 vs. 6.91 × 109/L, P = 0.36) at the time of granulocyte-colony stimulating factor (G-CSF) discontinuation, or safety of filgrastim and filgrastim-sndz. The efficacy and safety of filgrastim and filgrastim-sndz were similar for prophylaxis of chemotherapy-induced neutropenia and neutrophil recovery post-autologous HSCT.


Filgrastim Filgrastim-sndz Biosimilar Zarxio Neupogen 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Maschmeyer G, Rolston K. Myeloid growth factors. Infections in Hematology. Springer Berlin Heidelberg: 2015Google Scholar
  2. 2.
    Nahon S et al (2016) Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicenter study. Support Care Cancer 24:1991–1998CrossRefPubMedGoogle Scholar
  3. 3.
    Elayan MM et al (2015) Tbo-filgrastim versus filgrastim during mobilization and neutrophil engraftment for autologous stem cell transplantation. Biol Blood Marrow Transplant 21:1921–1925CrossRefPubMedGoogle Scholar
  4. 4.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: myeloid growth factors. Version 1.2017.
  5. 5.
    Renwick W, Pettengell R, Green M (2009) Use of filgrastim and pegfilgrastim to support delivery of chemotherapy. BioDrugs 23:175–186CrossRefPubMedGoogle Scholar
  6. 6.
    Hirsch BR, Lyman GH (2013) Will biosimilars gain momentum? J Natl Compr Cancer Netw 11:1291–1297CrossRefGoogle Scholar
  7. 7.
    Sorgel F et al (2015) Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs 29:123–131CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Zelenetz AD (2016) The role of biosimilars. J Natl Compr Cancer Netw 14(5):626–629CrossRefGoogle Scholar
  9. 9.
    Blackstone EA, Fuhr JP Jr (2012) Innovation and competition: will biosimilars succeed? Biotechnol Healthc 9:24–27PubMedPubMedCentralGoogle Scholar
  10. 10.
    Awad M et al (2017) Zarxio (filgrastim-sndz): the first biosimilar approved by the FDA. PT 42:19–23Google Scholar
  11. 11.
    Blackwell K et al (2015) Comparison of EP2006, a filgrastim biosimilar, to the reference: phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 26(9):1948–1953. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Harada K et al (2016) Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation. Int J Hematol 104:709–719CrossRefPubMedGoogle Scholar
  13. 13.
    Yoshimura H et al (2017) Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation. J Blood Med 8:5–12CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Julia Zecchini
    • 1
    Email author
  • Kendra Yum
    • 1
  • Amir Steinberg
    • 2
  • Cardinale Smith
    • 2
  • Sara Kim
    • 1
  1. 1.Department of PharmacyThe Mount Sinai HospitalNew YorkUSA
  2. 2.Division of Hematology/OncologyTisch Cancer InstituteNew YorkUSA

Personalised recommendations